0001493152-22-006543.txt : 20220310 0001493152-22-006543.hdr.sgml : 20220310 20220310171516 ACCESSION NUMBER: 0001493152-22-006543 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220309 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220310 DATE AS OF CHANGE: 20220310 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rennova Health, Inc. CENTRAL INDEX KEY: 0000931059 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 680370244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35141 FILM NUMBER: 22730086 BUSINESS ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 BUSINESS PHONE: 561-855-1626 MAIL ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 FORMER COMPANY: FORMER CONFORMED NAME: CollabRx, Inc. DATE OF NAME CHANGE: 20120926 FORMER COMPANY: FORMER CONFORMED NAME: TEGAL CORP /DE/ DATE OF NAME CHANGE: 19950918 8-K 1 form8-k.htm
0000931059 false 0000931059 2022-03-09 2022-03-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 or 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): March 9, 2022

 

Rennova Health, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-35141   68-0370244
(Commission File Number)   (I.R.S. Employer Identification No.)

 

400 South Australian Avenue, Suite 800,

West Palm Beach, Florida.

  33401
(Address of Principal Executive Offices)   (Zip Code)

 

(561) 855-1626
(Registrant’s Telephone Number, Including Area Code)

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered under Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
None   None   None

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 8.01. Other Events.

 

On March 9, 2022, the Board of Directors of Rennova Health, Inc. (the “Company”) approved an amendment to the Company’s Certificate of Incorporation (the “Amendment”), to effect a 1-for-10,000 reverse stock split of the Company’s shares of common stock to be effective on March 15, 2022. On December 15, 2021, the holders of a majority of the total voting power of the Company’s securities approved an amendment to the Company’s Certificate of Incorporation to effect a reverse split of all of the Company’s shares of common stock at a specific ratio within a range from 1-for-2,000 to 1-for-10,000, and granted authorization to the Board of Directors to determine in its discretion the specific ratio and timing of the reverse split on or prior to December 31, 2022.

 

As a result of the reverse stock split, every 10,000 shares of the Company’s pre-reverse split common stock will be combined and reclassified into one share of the Company’s common stock. Proportionate voting rights and other rights of common stockholders will not be affected by the reverse stock split, other than as a result of the cash payment for any fractional shares that would have otherwise been issued. Stockholders who would otherwise hold a fractional share of common stock will receive a cash payment in respect of such fraction of a share of common stock. No fractional shares will be issued in connection with the reverse stock split.

 

The reverse stock split will become effective at 5:00 p.m., Eastern Time, on March 15, 2022 and the Company’s common stock will trade on a post-split basis at the open of business on March 16, 2022. The par value and other terms of the common stock will not be affected by the reverse stock split. As described in the Company’s information statement, dated December 15, 2021, the holders of a majority of the total voting power of the Company’s securities also approved an increase in the authorized shares of our common stock from 50 billion to 250 billion shares.  The amendment to be filed with the Secretary of State of the State of Delaware to effect the reverse stock split will also include that increase in the authorized shares of common stock.

 

All outstanding preferred shares, stock options, warrants, and equity incentive plans immediately prior to the reverse stock split will generally be appropriately adjusted by dividing the number of shares of common stock into which the preferred shares, stock options, warrants and equity incentive plans are exercisable or convertible by 10,000 and multiplying the exercise or conversion price by 10,000, as a result of the reverse stock split.

 

The Company’s transfer agent, Computershare Inc., is acting as exchange agent for the reverse stock split and will as necessary send instructions to stockholders of record regarding the exchange of certificates for common stock.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Exhibit Description
     
99.1   Press Release dated March 10, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 10, 2022 RENNOVA HEALTH, INC.
     
  By: /s/ Seamus Lagan
    Seamus Lagan
    Chief Executive Officer
    (principal executive officer)

 

3

EX-99.1 2 ex99-1.htm

 

Exhibit 99.1 

 

 

RENNOVA HEALTH, INC. ANNOUNCES REVERSE STOCK SPLIT

 

WEST PALM BEACH, Fla. (March 10, 2022) – Rennova Health, Inc. (OTC: RNVA), today announced that effective at 5:00 pm, Eastern Time, on March 15, 2022 (the “Effective Time”), the Company will effect a 1 for 10,000 reverse stock split of its outstanding common stock. The Company’s common stock will open for trading on Wednesday March 16, 2022, on a post-split basis.

 

As a result of the reverse stock split, every 10,000 shares of the Company’s common stock issued and outstanding on the Effective Time will be consolidated into one issued and outstanding share, except to the extent that the reverse stock split results in any of the Company’s stockholders owning a fractional share, which fractional share will be in that case paid in cash. In connection with the reverse stock split, there will be no change in the nominal par value per share of $0.0001.

 

Trading of the Company’s common stock will continue, on a split-adjusted basis, with the opening of the markets on Wednesday March 16, 2022. Based on the number of shares currently outstanding on March 9, 2022, the reverse stock split will reduce the number of shares of the Company’s common stock outstanding from approximately 44 billion pre-reverse split shares to approximately 4.4 million post-reverse split.

 

All outstanding preferred shares, stock options, warrants, and equity incentive plans immediately prior to the reverse stock split generally will be appropriately adjusted by dividing the number of shares of common stock into which the preferred shares, stock options, warrants and equity incentive plans are exercisable or convertible by 10,000 and multiplying the exercise or conversion price by 10,000, as a result of the reverse stock split.

 

The Company has retained its transfer agent, Computershare, Inc., to act as its exchange agent for the reverse stock split. As necessary, Computershare will provide stockholders of record as of the Effective Time a letter of transmittal providing instructions for the exchange of their stock certificates. Stockholders owning shares via a broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers’ particular processes, and will not be required to take any action in connection with the reverse stock split.

 

The reverse stock split was approved by the directors of the Company on March 9, 2022, pursuant to a resolution adopted by written consent of the holders of the majority of the total voting power of the Company’s securities on December 15, 2021.

 

About Rennova Health, Inc.

 

Rennova is a provider of health care services to rural communities. The Company owns one operating acute care hospital in Oneida, Tennessee known as Big South Fork Medical Center (classified as a critical access hospital), an acute care hospital and physician’s office located in Jamestown, Tennessee that it plans to reopen and operate, and a rural clinic in Kentucky. For more information, please visit www.rennovahealth.com

 

Forward-Looking Statements

 

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company’s most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

 

Contact:

 

Rennova Health

561-855-1626

info@rennovahealth.com

 

 

 

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 rnva-20220309.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 rnva-20220309_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 rnva-20220309_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover
Mar. 09, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 09, 2022
Entity File Number 001-35141
Entity Registrant Name Rennova Health, Inc.
Entity Central Index Key 0000931059
Entity Tax Identification Number 68-0370244
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 400 South Australian Avenue
Entity Address, Address Line Two Suite 800
Entity Address, City or Town West Palm Beach
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33401
City Area Code 561
Local Phone Number 855-1626
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000931059 2022-03-09 2022-03-09 iso4217:USD shares iso4217:USD shares 0000931059 false 8-K 2022-03-09 Rennova Health, Inc. DE 001-35141 68-0370244 400 South Australian Avenue Suite 800 West Palm Beach FL 33401 561 855-1626 false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY M%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;:< MW@(2* 0I*-D1>X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(\4I! MK-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H M%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.L ML8DF"=9#;E9T!N[RZ .;O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0 ( .:):E0D'INBK0 M /@! : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2 MY0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D M1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " #FB6I499!Y MDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE M+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WU MV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R M;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@ M9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M! M3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ M 0(4 Q0 ( .:):E0'04UB@0 +$ 0 " 0 !D M;V-0&UL4$L! A0#% @ YHEJ5#=]S;#M *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ MYHEJ5)E&PO=V]R:W-H965T&UL4$L! A0#% @ MYHEJ5)^@&_"Q @ X@P T ( !+0P 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ YHEJ M5"0>FZ*M ^ $ !H ( !4A$ 'AL+U]R96QS+W=O9(9 0 SP, !, M ( !-Q( %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& D "0 ^ ) @ @1, end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 122 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://rennovahealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm rnva-20220309.xsd rnva-20220309_lab.xml rnva-20220309_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "rnva-20220309_lab.xml" ] }, "presentationLink": { "local": [ "rnva-20220309_pre.xml" ] }, "schema": { "local": [ "rnva-20220309.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "RNVA", "nsuri": "http://rennovahealth.com/20220309", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-03-09to2022-03-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://rennovahealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-03-09to2022-03-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001493152-22-006543-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-006543-xbrl.zip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end